Depression and RA (3.8.2024)

Jack Cush, MD

Mar 07, 2024 10:22 pm

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week.

Sandoz has announced FDA approval for their two interchangeable biosimilars of denosumab - Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) based on reference products Xgeva and Prolia https://t.co/5OmJHDYWmM
Frensius-Kabi has announced that the FDA has approved the tocilizumab biosimilar, Tyenne (tocilizumab-aazg); the first TCZ biosimilar with both IV and subcutaneous formulations https://bit.ly/49UTfqQ
Stills Dz Rx w/ IL-1 or IL-6 inhib may mask Dx of MAS! Study of 162 systemic JIA & MAS (62 on biologics). Biologic Rx pts had lower Plt, Ferritin (1107 vs 2863(, CRP (15 vs 90), ESR, fever duration. 27% on IL1/IL6i did not meet MAS classification criteria https://t.co/RmAzxh459R
EMR study identified 3.5+ million pts w/ BMI >30 -- 23% had sleep apnea (OSA). OSA had >2 fold risk of gout (7.2% vs 2.8%)vs those without OSA (p<0.0001). The odds of having gout are 2.65 times higher(HR 2.39; (CI) 2.367-2.419, p<0.0001). https://t.co/GgWrAiFPds
COVIDs Extended Risk for Rheumatic Disease Annals of Internal Medicine reports a large, binational study finding SARS-CoV-2 infection was associated with an increased risk for AIRDs that extends up to 12 months after infection. https://t.co/AIFc3B2YDP
85 pts w/ Myositis by MRI. Abnl MRI patterns correlated w/: - Honeycomb & foggy w TIF1γ or Mi2+, MSA-neg DM/PM, SRP+, HMGCR+ - Honeycomb w Cancer (OR 6.8), Gottrons(OR 8) - Foggy w weakness (OR 11.2) - Dense dot w dysphagia (OR 6.3) & CA https://t.co/kZGuNLFglg
Machine learning of 701 Anti-Synthetase (Anti-Jo1, -PL7, -PL12, -EJ) identifies 3 Endotypes,independent Ab specificity #1 (24%) w/ RP-ILD & high mortality #2 (14%) dermatomyositis, intermediate prognosis #3 (62%) arthritis & mechanics hands, good prognosis https://t.co/y9LMCfMIgN
DESIR study: new onset SpA pts followed w/ Xrays x 10 yrs showed progression from nr-axSpA to r-axSpA was 5.8% (in 294 followed 10 yrs), best predicted by baseline SI bone marrow edema, (OR 6.2), male, Sxs >1.5 yr, ASDAS ≥2.1 & smoking (only in HLA-B27+). https://t.co/A3Qqy8Eeym
Cross-sectional multicenter study of 500 ax-SpA pts on biologics found 25% w/ Irritable Bowel Syndrome (IBS) that was linked to being Female gender, unemployed, higher BASDAI & BASFI, multiple biologics, FM , anxiety, depression & lower physical activity. https://t.co/RSKVcXZwLt
Increased Depression on Rheumatoid Arthritis
19% Arthritis Prevalence in the USA